Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSC | P53634 | 20/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.50 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.50 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.50 |
| ▸ | CTSK | P43235 | 3/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2072188 | 0.82 | CTSC (0.53) | CTSCCTSK | |
| SCHEMBL2072191 | 0.82 | CTSC (0.53) | CTSCCTSK | |
| SCHEMBL289950 | 0.80 | CTSC (0.67) | CTSCKCNH2LTB4RLTB4R2CTSK | |
| SCHEMBL2072367 | 0.80 | CTSC (0.47) | CTSCKCNH2CTSK | |
| SCHEMBL2072370 | 0.80 | CTSC (0.47) | CTSCKCNH2CTSK | |
| SCHEMBL30738906 | 0.79 | CTSC (0.51) | CTSCKCNH2CTSK | |
| SCHEMBL30738872 | 0.79 | CTSC (0.56) | CTSCKCNH2CTSK | |
| SCHEMBL30738936 | 0.78 | CTSC (0.56) | CTSCKCNH2CTSK | |
| SCHEMBL12383351 | 0.78 | CTSC (0.53) | CTSCKCNH2CTSK | |
| SCHEMBL16932243 | 0.78 | CTSC (0.61) | CTSCKCNH2CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11655223-B2 | Certain (2S)-N-[(1 s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors | ASTRAZENECA AB (SE) | 2023-05-23 | — | — | US | disclosed |
| US-20230028726-A1 | CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE 1 INHIBITORS | BIOPHARMA CREDIT PLC (GB) | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230028726-A1 | CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE 1 INHIBITORS | DPP4, DPP7, DPEP1 | CTSC 7/4885KCNH2 2475/4885LTB4R 636/4885 |
| US-11655223-B2 | Certain (2S)-N-[(1 s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors | DPP4, DPP7, DPP3 | CTSC 7/4885KCNH2 2492/4885LTB4R 579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.